Abstract
Dementia represents a major problem of health and disability, with a relevant economic impact on our society. Despite important advances in pathogenesis, diagnosis and treatment, its primary causes still remain elusive, accurate biomarkers are not well characterized, and the available pharmacological treatments are not cost-effective. Alzheimer disease (AD), the most prevalent form of dementia, is a polygenic/multifactorial/complex disorder in which hundreds of defective genes distributed across the human genome may contribute to its pathogenesis. Diverse environmental factors, cerebrovascular dysfunction, and epigenetic phenomena, together with structural and functional genomic dysfunctions lead to amyloid deposition, neurofibrillary tangle formation and premature neuronal death, the major neuropathological hallmarks of AD. For the past 20 years, over 1,000 different compounds have been studied as potential candidate drugs for the treatment of AD. About 50% of these substances are novel molecules obtained from natural sources. The candidate compounds can be classified according to their pharmacological properties and/or the AD-related pathogenic cascade to which they are addressed to halt disease progression. In addition to th...Continue Reading
Citations
Sep 15, 2017·Evidence-based Complementary and Alternative Medicine : ECAM·Taiwo Olayemi ElufioyeSolomon Habtemariam
Dec 14, 2019·Journal of Clinical Psychopharmacology·Laura BorghansArjan Blokland
Mar 15, 2020·Nutrients·Lola CorzoRamón Cacabelos
Apr 22, 2017·CNS Neuroscience & Therapeutics·Lan-Xue ZhaoYu Qiu
Jul 7, 2018·CNS Neuroscience & Therapeutics·Hei-Jen HuangHsiu Mei Hsieh-Li
Jul 24, 2018·International Journal of Alzheimer's Disease·Aristo Vojdani, Elroy Vojdani
Jun 12, 2018·Neurodegenerative Disease Management·Andrea Stoccoro, Fabio Coppedè
Mar 16, 2019·International Journal of Molecular Sciences·Ramón CacabelosDmitry Goldgaber
Aug 12, 2020·Synapse·Alfonso DiazJorge Guevara
Jan 6, 2018·Journal of Personalized Medicine·Ramón CacabelosÓscar Teijido
Apr 3, 2018·Expert Opinion on Drug Discovery·Ramón Cacabelos
Jan 29, 2020·Current Neuropharmacology·Vivek Kumar SharmaThakur Gurjeet Singh
Dec 12, 2020·Chemico-biological Interactions·Mingfei WuZeng Li
Aug 20, 2020·Seminars in Cancer Biology·Margarita E NeganovaGjumrakch Aliev
Jun 14, 2016·Pharmacogenomics·Ramón CacabelosJuan Carlos Carril